PT  - JOURNAL ARTICLE
AU  - Marsh-Wakefield, Felix
AU  - Santhakumar, Cositha
AU  - Ferguson, Angela L.
AU  - Ashhurst, Thomas M.
AU  - Shin, Joo-Shik
AU  - Guan, Fiona H. X.
AU  - Shields, Nicholas J.
AU  - Platt, Barry J.
AU  - Putri, Givanna H.
AU  - Gupta, Ruta
AU  - Crawford, Michael
AU  - Pulitano, Carlo
AU  - Sandroussi, Charbel
AU  - Laurence, Jerome M.
AU  - Liu, Ken
AU  - McCaughan, Geoffrey W.
AU  - Palendira, Umaimainthan
TI  - Spatial mapping of the hepatocellular carcinoma landscape identifies unique intratumoural perivascular-immune neighbourhoods
AID  - 10.1101/2023.09.15.23295451
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2023.09.15.23295451
4099  - http://medrxiv.org/content/early/2024/02/06/2023.09.15.23295451.short
4100  - http://medrxiv.org/content/early/2024/02/06/2023.09.15.23295451.full
AB  - Background & Aims Hepatocellular carcinoma (HCC) develops in the context of chronic inflammation, however, the opposing roles the immune system plays in both the development and control of tumours is not fully understood. Mapping immune cell interactions across the distinct tissue regions could provide greater insight into the role individual immune populations have within tumours.Methods A 39-parameter imaging mass cytometry panel was optimised with markers targeting immune cells, stromal cells, endothelial cells, hepatocytes, and tumour cells. We mapped the immune landscape of tumour, invasive margin, and adjacent non-tumour regions across sixteen resected tumours comprising of 144 regions of interest. X-shift clustering and manual gating were used to characterise cell subsets, and Spectre quantified the spatial environment to identify cellular neighbourhoods. Ligand-receptor communication was quantified on two single-cell RNA-sequencing datasets and one spatial transcriptomic dataset.Results We show immune cell densities remain largely consistent across these three regions, except for subsets of monocyte-derived macrophages which are enriched within the tumours. Mapping cellular interactions across these regions in an unbiased manner identifies immune neighbourhoods comprised of tissue-resident T cells, dendritic cells, and various macrophage populations around perivascular spaces. Importantly, we identify multiple immune cells within these neighbourhoods interacting with VEGFA+ perivascular macrophages. VEGFA was further identified as a ligand for communication between perivascular macrophages and CD34+ endothelial cells.Conclusions Immune cell neighbourhood interactions, but not cell densities, differ between intratumoural and adjacent non-tumour regions in HCC. Unique intratumoural immune neighbourhoods around the perivascular space points to an altered landscape within tumours. Enrichment of VEGFA+ perivascular macrophages within these tumours could play a key role in angiogenesis and vascular permeability.Impact and Implications We investigated the landscape of immune cells within liver cancer. A unique perivascular neighbourhood of immune cells was identified. This is important as the interaction of immune cells and the vasculature in liver cancer is a therapeutic target of current systemic therapy. The characterisation in detail of this neighbourhood may potentially identify additional targets for future therapies.Imaging mass cytometry using 39 markers was used to map immune-infiltrating cells in hepatocellular carcinoma (HCC)Perivascular macrophages (PVM) were seen to form unique intratumoural neighbourhoods with immune cellsPVM were identified as VEGFA+ within HCC tumoursCompeting Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by the Joan Krefft bequest to the A.W. Morrow Gastroenterology and Liver Centre (Royal Prince Alfred Hospital) and Cancer Institute NSW (2021/ATRG2028). Felix Marsh-Wakefield is supported by the International Society for the Advancement of Cytometry (ISAC) Marylou Ingram Scholars Program. Cositha Santhakumar is supported by the Sydney Cancer Partners PhD scholarship.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional human research ethics was obtained by the Sydney Local Health District Ethics Review Committee (HREC 2020/ETH02093). Research was conducted in accordance with both the Declarations of Helsinki and Istanbul, with written consent given in writing by all subjects.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData are available on Zenodo (DOI 10.5281/zenodo.10547481).FFPEFormalin-fixed paraffin embeddedH&EHaematoxylin and eosinHCCHepatocellular carcinomaIHCImmunohistochemistryIMCImaging mass cytometryLSECLiver sinusoidal endothelial cellMAITcells mucosal-associated invariant T cellsmIHCMultiplex immunohistochemistryMRSmyeloid response scoreMVIMicrovascular invasionPCAPrincipal component analysisPERMANOVAPermutational multivariate analysis of variancePVMperivascular macrophageROIRegion of interestRTRoom temperaturescRNA-seqSingle-cell RNA-sequencingsPLS-DASparse partial least squares-discriminant analysisTAMtumour-associated macrophageTGF-βtransforming growth factor-betaTILTumour-infiltrating lymphocyteTMATissue microarrayTMETumour immune microenvironmentTNMTumour-node-metastasisTSATyramide signalling amplificationVEGFAVascular endothelial growth factor A